Reuters logo
BRIEF-European Medicines Agency begins evaluation of marketing application for sublingual Sufentanil
March 28, 2017 / 11:12 AM / in 7 months

BRIEF-European Medicines Agency begins evaluation of marketing application for sublingual Sufentanil

March 28 (Reuters) - Acelrx Pharmaceuticals Inc

* European Medicines Agency begins evaluation of marketing application for sublingual Sufentanil 30 mcg tablet (ARX-04) for moderate-to-severe acute pain

* Acelrx expects an opinion on MAA from committee for medicinal products for human use (CHMP) in first half of 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below